• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie touts late-stage safety data for Roclatan eye drops

July 21, 2017 By Sarah Faulkner

AerieAerie Pharmaceuticals (NSDQ:AERI) touted 12-month safety data yesterday from the Phase III registration trial of its Roclatan eye drops for intraocular pressure resulting from glaucoma or ocular hypertension.

The study was designed to support Aerie’s new drug application submission to the FDA for Roclatan, which it expects to file in the first half of next year.

Safety data for the 12-month study period were consistent with results observed during the 90-day efficacy period in the Mercury 1 trial. Aerie reported that there were no new adverse events that developed following the initial 90-day period.

The most common adverse event was eye redness, which was reported in 60% of patients.

Intraocular pressure was also measured throughout the 12-month study period, Aerie said, and Roclatan lowered IOP better than latanoprost and Aerie’s Rhopressa – consistent with results observed in the initial 90-day study period.

“With these positive 12-month Mercury 1 data, we have again demonstrated the consistent and well-understood performance of Roclatan and Rhopressa from both a safety and efficacy perspective. Roclatan™ has the potential to become the most efficacious IOP-lowering therapy to enter the market, if approved, bolstered by an overall favorable safety and tolerability profile. We continue to expect to submit our Roclatan NDA in the first half of 2018,” chairman & CEO Vicente Anido, Jr., said in prepared remarks.

“This data readout represents the last in our series of Phase III trials for both Roclatan and Rhopressa for approval in the U.S., and we are now actively engaged in preparations for the expected Rhopressa commercialization next year.”

“As a clinician, I am very excited about the responder analysis data for Roclatan showing such a profound drop in IOP,” chief medical officer Dr. Richard Lewis added. “We now have a robust understanding of the Roclatan safety profile and expect that clinicians will be highly satisfied with the 12-month safety and efficacy data.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Wall Street Beat Tagged With: Aerie Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS